What’s New?

Slide
Patient Testimonials
We’ve added a brand-new section to our website! You can now read real stories from our patients.
CLICK HERE TO ACCESS THE PATIENT TESTOMONIALS
previous arrowprevious arrow
next arrownext arrow

The successful 15 year results of the PATCH/STAMPEDE Phase-III trials are now published in the New England Journal of Medicine.

Click here to see the paper!

Estradiol and ADT: Lessons from Lived Experience Videos

Click here to watch 5 videos by Richard Wassersug and Paul Schellhammer discussing the Estradiol Initiative, a movement advocating for transdermal estradiol as a standard-of-care option for androgen deprivation therapy (ADT) in men with advanced prostate cancer. 

Mission Statement

Our mission is to educate patients and clinicians about the benefits and risks of using transdermal estradiol (tE2) for men receiving Androgen Deprivation Therapy (ADT) for prostate cancer. Our main goal is to secure FDA and NCCN approval for tE2 ADT as a Standard of Care for these patients.

Background

Findings from the PATCH/STAMPEDE trial in the UK indicate that estradiol tE2 provides as good survival for prostate cancer (PCa) patients when used for androgen deprivation therapy (ADT) as the standard, approved drugs for androgen suppression. Furthermore, the PATCH/STAMPEDE research team previously demonstrated that patients have overall better quality of life when on tE2. Patients have, for example, significantly fewer hot flashes, better sleep, less fatigue, and lower risk of osteoporosis.

There are, however, no tE2 products on the market that have been tested and licensed for men with prostate cancer.

What are we doing?

Research…

  • on prostate cancer patients’ interest in alternative forms of ADT.
  • on the costs and benefits of various tE2 products on the market and ways to make tE2 products both cheaper and more available to prostate cancer patients.
  • in collaboration with scientists in the USA and UK, we are studying the quality of life benefits of estradiol for men on ADT.

Outreach to…

  • patients via support organizations in Canada, the USA, and beyond, with in-person presentations and chat group participation.
  • physicians through individual contacts and professional medical societies to inform them of the survival and quality of life benefits of ADT with tE2.
  • Pharma to encourage their development of tE2 products, then testing and licensing the products so they can become officially approved standards of care for prostate cancer patients.

Fundraising… 

  • to generate enough funding through private and public donations to enable the creation and licensing of one or more tE2 products for men with prostate cancer.

The contributors to this website have no conflicts of interest, and they do not receive any money from selling estradiol products or from corporate sponsorships.